

Form PTO-1449

**U.S. Department of Commerce
Patent and Trademark Office**

Atty. Docket No.

44657-AAA-PCT-US

Serial No.

10/052,961

INFORMATION DISCLOSURE CITATION
(Use several sheets if necessary)

Applicant:

Joseph R. Berger

Filing Date

January 18, 2002

Group

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
✓	US 5 8 7 2 1 4 7	2/16/99	Bowen			
✓	US 6 5 7 6 6 5 9	6/10/03	Fishbein			
✓	US 6 6 7 0 3 5 1	12/30/03	Berger			

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Subclass	Translation
					Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


✓	U.S. Published Application No. 2002/0091155, Published July 11, 2002, Berger (Exhibit 4);
✓	U.S. Published Application No. 2003/0049716, Published March 13, 2003, Barton and Kramer. (Exhibit 5);
✓	U.S. Serial No. 10/799,264, filed March 12, 2004, Fishbein (Exhibit 6);
✓	U.S. Serial No. 10/799,197, filed March 12, 2004, Fishbein (Exhibit 7);
✓	Chicago Tribune, (Sep. 20, 1991), North Sports Final edition, Business Section, page 1 (Exhibit 8);
✓	Demling and DeSanti, (1997), "Oxandrolone, an Anabolic Steroid, Significantly Increases the Rate of Weight Gain in the Recovery Phase After Major Burns," <i>J. Trauma</i> , Vol. 43, No. 1, pp. 47-51 (Exhibit 9);
✓	Demling and DeSanti, (October 1998), "Closure of the 'Non-Healing Wound' Corresponds with Correction of Weight Loss Using the Anabolic Agent Oxandrolone," <i>Ostomy/Wound Management</i> , Vol. 44, No. 10, pp. 58-60, 62, 64, 66, 68 (Exhibit 10);
Not supplied	Demling, (1999), "Comparison of the Anabolic Effects and Complications of Human Growth Hormone and the Testosterone Analog, Oxandrolone, After Severe Burn Injury," <i>Burns</i> , Vol. 25, pp. 215-221 (Exhibit 11);
✓	Demling, (Mar-Apr 2000), "Oxandrolone, an Anabolic Steroid, Enhances the Healing of a Cutaneous Wound in the Rat," <i>Wound Repair Regen.</i> , Vol. 8, No. 2, pp. 97-102 (Exhibit 12);
Not supplied	Demling and DeSanti, (2001), "The Rate of Restoration of Body Weight After Burn Injury, Using the Anabolic Agent Oxandrolone, is not Age Dependent," <i>Burns</i> , Vol. 17, pp. 46-51 (Exhibit 13);
✓	Demling and DeSanti, (September/October 2001), "The Anabolic Steroid, Oxandrolone, Reverses the Wound Healing Impairment in Corticosteroid-Dependent Burn and Wound Patients," <i>Wounds</i> , Vol. 13, No. 5, pp. 203-207 (Exhibit 14);
✓	DeSanti et al., (1998), "Development of a Burn Rehabilitation Unit: Impact on Burn Center Length of Stay and Functional Outcome," <i>Journal of Burn Care & Rehabilitation</i> , Vol. 19, No. 5, pp. 414-419 (Exhibit 15);
✓	Ehrlich and Hunt, (August 1969), "The Effects of Cortisone and Anabolic Steroids on the Tensile Strength of Healing Wounds," <i>Ann Surg.</i> , Vol. 170, No. 2, pp. 203-206 (Exhibit 16);
✓	Eisenberg, (1966), 65 <i>Chemical Abstracts</i> :40387 (Exhibit 17);
✓	Eisenberg, (May 1966), "Effects of Androgens, Estrogens and Corticoids on Strontium Kinetics in Man," <i>J. Clin. Endocr.</i> , Vol. 26, pp. 566-572 (Exhibit 18);
✓	Ferraresi, (April 1996), "Clinical Profile of Oxandrin," BTG Pharmaceuticals (Exhibit 19);
✓	Grant, (1980), "Patient Selection," <i>Handbook of Total Parenteral Nutrition</i> , Saunders, pp. 7-46 (Exhibit 20);

EXAMINER

DATE CONSIDERED

6/9/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Atty. Docket No. 44657-AAA-PCT-US		Serial No. 10/052,961	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Applicant: Joseph R. Berger			
				Filing Date January 18, 2002		Group	
U.S. PATENT DOCUMENTS							
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Subclass	Translation
							Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
✓		Hausmann et al., (March/April 1990), "Anabolic Steroids In Polytrauma Patients. Influence on Renal Nitrogen and Amino Acid Losses: A Double Blind Study," <i>J. Parent. Enteral. Nutr.</i> , Vol. 14, No. 2, pp. 111-114 (Exhibit 21);					
✓		Helfman and Falanga, (August 1995), "Stanozolol as a Novel Therapeutic Agent in Dermatology," <i>J. of the American Acad. of Dermatology</i> , Vol. 33, No. 2, pp. 254-258 (Exhibit 22);					
✓		Jekot and Purdy, (April 1993), "Treating HIV/AIDS Patients with Anabolic Steroids," <i>AIDS Patient Care</i> , pp. 68-74 (Exhibit 23);					
✓		Koehler et al., (1998), "Achieving Healing of 'Non-Healing Pressure Ulcers," 1998 WOCN 30th Annual Conference, p. 37 (Exhibit 24);					
✓		Kotler, (1996), "Dilemmas in the Treatment of Weight Loss," BTG Pharmaceuticals, pp. 1-7 (Exhibit 25);					
✓		Levien et al., (July 1994), "Reviews of Trimetrexate and Oxandrolone," <i>Hospital Pharmacy</i> , Vol. 29, No. 7, pp. 696-702, 705-708 (Exhibit 26);					
✓		Martindale, (1982), <i>The Extra Pharmacopoeia 28th Edition</i> , The Pharmaceutical Press, London, Reynolds and Prasad Eds., p. 1430 (Exhibit 27);					
✓		PR Newswire, 0828P8715, (August 28, 1991), "Gynex Obtains International Rights to Drug to Treat For Growth Disorders, AIDS" (Exhibit 28);					
✓		Schwartz and Miller, (1986), "Androgens and Anabolic Steroids," in <i>Modern Pharmacology, Second Edition</i> , Little Brown and Company, Boston/Toronto, Craig and Stitzel Eds., pp. 905-924 (Exhibit 29);					
✓		Tennenbaum and Shklar, (December 1970), "The Effect of an Anabolic Steroid on the Healing of Experimental Extraction Wounds," <i>Oral Surg.</i> , Vol. 30, No. 6, pp. 824-834 (Exhibit 30); and					
✓		Udupa and Chansouria, (March 1969), "Studies on Wound Healing," <i>Indian J. Med. Res.</i> , Vol. 57, pp. 434-456 (Exhibit 31).					
EXAMINER				DATE CONSIDERED 6/9/04			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							